|
市場調査レポート
商品コード
1374851
皮膚科用エキシマレーザーの世界市場-2023年~2030年Global Dermatology Excimer Laser Market - 2023-2030 |
||||||
カスタマイズ可能
適宜更新あり
|
皮膚科用エキシマレーザーの世界市場-2023年~2030年 |
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 187 Pages
納期: 即日から翌営業日
|
皮膚科用エキシマレーザーは、紫外線B(UVB)を用いたレーザー光で皮膚の患部を治療するレーザー治療器です。このレーザー治療は、頭皮を含め、体のあらゆる部位を治療することができます。これらのレーザーによる様々な皮膚疾患の治療は、非常に効果的で、安全かつ無痛であると考えられています。エキシマレーザーは、露出している全ての皮膚を治療する光線治療器とは対照的に、皮膚の患部のみを治療します。治療時間は通常10~15分未満です。
さらに、皮膚科用エキシマレーザーでは、光は波長で伝わり、非常に長い波長の光もあれば、非常に短い波長の光もあります。異なる波長の光は、体に異なる影響を与えることができます。この波長の光は、湿疹の症状を引き起こす過剰な免疫細胞を除去し、白斑の影響を受けた皮膚の色素沈着を改善することができます。エキシマレーザー治療は、乾癬が肘、手、足、頭皮などの小さな皮膚に限局している場合にも治療できます。これらのレーザーは、このような皮膚症状に最も一般的に使用されています。
様々な皮膚疾患における皮膚科用エキシマレーザーの採用の増加とエキシマレーザーの進歩の増加は、予測期間にわたって市場を牽引すると予測されます。皮膚科用エキシマレーザー技術の継続的な進歩は、特に白斑や乾癬に対して、さらに精密でカスタマイズ可能な治療オプションにつながっています。その結果、健康な組織へのダメージが減少し、より迅速で効果的な治療が可能です。
例えば、2022年2月9日、STRATA Skin Sciences, Inc.は、次世代エキシマレーザーシステムXTRAC Momentum 1.0の米国市場における最初の設置を開始しました。XTRACエキシマレーザー技術は、乾癬、アトピー性皮膚炎、白斑などの炎症性皮膚疾患に悩む成人および小児患者を対象に、特定の皮膚治療部位にターゲットを絞ったUVB光治療を正確に照射することを可能にします。
さらに、STRATA社の新型XTRAC Momentum 1.0は、最新のエキシマレーザー技術を搭載し、現行モデルよりも高い出力と高速の繰り返し周波数を実現しています。Momentumはまた、新しいユーザーインターフェースとスリムなデザインを提供し、どちらも治療体験を向上させることを目的としています。
加えて、エキシマレーザーは乾癬治療に特に効果的です。エキシマレーザーは、患部を正確に狙い撃ちし、健康な皮膚への照射を減らすことができます。このため、乾癬患者の主な治療オプションとしてエキシマレーザーの採用が増加しています。エキシマレーザーの標的を絞る性質は、白斑患者にとっても有益であり、患部の色素再形成を助けることができます。患者はますます非侵襲的で高度な標的治療を求めるようになっており、皮膚科用エキシマレーザーの採用に貢献しています。
例えば、2020年8月12日、美容・医療皮膚科用の世界トップクラスのレーザー機器を開発・製造するLASEROPTEK株式会社は、米国でPALLAS Solid-State 311nm UVBレーザーを発売しました。効果的で安全なPALLASレーザーは、白斑、乾癬、アトピー性皮膚炎、白皮症の治療用としてFDAの認可を受けています。PALLASは、308ナノメートルのエキシマレーザーを超える独自の技術改良を特徴としています。
さらに、乾癬、尋常性白斑、湿疹などの慢性皮膚疾患の有病率の増加、より先進的なレーザーのFDA承認の増加、より精密なエキシマレーザーの認知度の向上と市場発展の進展は、予測期間中に市場を牽引すると予想される要因です。
皮膚科用エキシマレーザーに関連する合併症、エキシマレーザー治療の高コスト、これらのレーザー技術に関連する副作用、エキシマレーザーに関する認識不足などの要因が市場を阻害すると予想されます。
Dermatology excimer laser is a device used for laser therapy by using the laser beam with ultraviolet B (UVB) light to treat the affected areas of skin. Any area of the body can be treated with this laser therapy, including the scalp. The treatment of various skin conditions with these lasers is considered highly effective, safe and painless. The excimer laser treats only the affected areas of skin as opposed to a phototherapy unit which treats all exposed skin. Treatment time is typically less than 10-15 minutes.
Moreover, in dermatology excimer lasers, light travels in waves, some types of light waves are very long and other wavelengths are quite short. Light of different wavelengths can have different effects on the body. This wavelength of light can eliminate the overactive immune cells that cause symptoms of eczema and can help re-pigment skin affected by vitiligo. Excimer laser treatments can also treat psoriasis when the condition is confined to smaller patches of skin, such as the elbows, hands, feet, or scalp. These lasers are most commonly used for such skin conditions.
The increasing adoption of dermatology excimer lasers in various skin disorders and increasing advancements in excimer lasers are expected to drive the market over the forecast period. Ongoing advancements in dermatology excimer laser technology led to even more precise and customizable treatment options, especially for vitiligo and psoriasis. This results in reduced damage to healthy tissue and quicker, more effective treatments.
For instance, on February 09, 2022, STRATA Skin Sciences, Inc. launched the first installation in the U.S. market, of its next-generation excimer laser system, XTRAC Momentum 1.0. The XTRAC excimer laser technology allows for the precise delivery of targeted UVB light therapy to specific skin treatment areas, for both adult and pediatric patients suffering from inflammatory skin conditions such as psoriasis, atopic dermatitis and vitiligo.
Moreover, STRATA's new XTRAC Momentum 1.0 represents the latest in excimer laser technology, delivering higher power and a faster repetition rate than the current models. The Momentum also offers a new user interface and slim design, both intended to improve the treatment experience.
In addition, excimer lasers are particularly effective in treating psoriasis. They offer precise targeting of affected areas, reducing exposure to healthy skin. This has led to increased adoption of excimer lasers as a primary treatment option for psoriasis patients. The targeted nature of excimer laser therapy is also beneficial for vitiligo patients, where it can help repigment the affected areas. Patients are increasingly seeking non-invasive and highly targeted treatments, contributing to the adoption of the dermatology excimer lasers.
For instance, on August 12, 2020, LASEROPTEK Co., Ltd., a developer and manufacturer of world-class laser devices for aesthetic and medical dermatology, launched its PALLAS Solid-State 311nm UVB laser in the United States. The efficacious and safe PALLAS laser is FDA-cleared for the treatment of vitiligo, psoriasis, atopic dermatitis and leukoderma. PALLAS features unique technology improvements over 308-nanometer excimer lasers.
Further, the increasing prevalence of chronic skin conditions like psoriasis, vitiligo, eczema and others, rising FDA approvals for more advanced lasers, increasing awareness and advancements in the development of more precise excimer lasers are the factors expected to drive the market over the forecast period.
Factors such as complications associated with dermatology excimer lasers, high cost of the excimer laser therapy, side effects associated with these laser techniques and lack of awareness about the excimer lasers are expected to hamper the market.
The global dermatology excimer laser market is segmented based on product type, application, end-user and region.
The psoriasis segment is expected to hold the largest market share over the forecast period. The dermatology excimer lasers emit a specific wavelength of ultraviolet B light, which can be precisely targeted to affected areas of the skin. This focused treatment minimizes exposure to healthy skin, reducing the risk of side effects commonly associated with broader UVB exposure. In case of psoriasis, excimer lasers are used to slow down the growth of skin cells in affected areas and reduce inflammation, helping to manage and alleviate the symptoms of psoriasis.
Additionally, using excimer lasers for psoriasis patients results in faster clearing of psoriatic lesions compared to other treatment methods and the therapy is generally well-tolerated so this therapy is most commonly used. Patients are mostly preferring this therapy due to its non-invasive nature.
Moreover, the increasing prevalence of psoriasis is expected to the increasing adoption of dermatology excimer lasers. For psoriasis patients, excimer laser therapy provides relief that lasts several months, improves symptoms in just 6-12 sessions, is known for a quick, easy treatment that doesn't require to application of creams or products every day, provides long-term symptom remission and it also provides pain-free and non-invasive treatment.
For instance, according to the National Psoriasis Foundation, 2022, more than 8 million Americans have psoriasis. 125 million people worldwide, 2 to 3 percent of the total population have psoriasis, according to the World Psoriasis Day consortium. Psoriasis prevalence in African Americans is 1.5 percent compared to 3.6 percent of Caucasians.
North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing adoption of dermatology excimer lasers to treat various types of skin conditions. North America especially the United States is known for its strong presence of major players such as medical device companies and biotechnology companies which are actively focussing on the development of more advanced and precise dermatology excimer lasers for better patient outcomes. This presence of major players performs research activities for the advancements in the excimer lasers.
Furthermore, increasing adoption of dermatology excimer lasers is also expected to drive the market in the region. The region is also known for the increasing prevalence of various skin conditions, this increasing prevalence is expected to increase the demand and adoption of dermatology excimer lasers.
For instance, according to the National Eczema Association, 31.6 million people in the U.S. have some form of eczema, and prevalence peaks during early childhood and according to the National Psoriasis Foundation, more than 8 million Americans have psoriasis. This increasing prevalence of skin conditions in the region is expected to increase the adoption of dermatology excimer lasers for better treatment of skin disorders.
The major global players in the dermatology excimer laser market include: STRATA Skin Sciences, Inc., Shenzhen GSD Tech Co., Ltd., Alma Lasers, Kernel Medical Equipment Co., LTD., Timpac Healthcare Pvt. Ltd., KRUPA MEDI SCAN, Komachine Inc., Optosystems Ltd., DermSA and PhotoMedex, Inc. among others.
The COVID-19 pandemic significantly impacted the global dermatology excimer laser market. During the pandemic, patients with dermatological conditions like psoriasis, who would have otherwise sought treatment with excimer lasers are delayed or avoided in-person visits to healthcare facilities. This was due to concerns and redirected focus towards virus exposure, restrictions on non-essential healthcare services and the reprioritization of healthcare resources. The pandemic also disrupted the supply chain of these medical devices globally due to border closures.
The global dermatology excimer laser market report would provide approximately 61 tables, 61 figures, and 187 Pages.
LIST NOT EXHAUSTIVE